COVID-19 and the Heart and Vasculature

Year: 2020

Type: article

Abstract: The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented challenge and opportunity for translational investigators to rapidly develop safe and effective therapeutic interventions. Greater risk of severe disease in COVID-19 patients with comorbid diabetes mellitus, obesity, and heart disease may be attributable to synergistic activation of vascular inflammation pathways associated with both COVID-19 and cardiometabolic disease. This mechanistic link provides a scientific framework for translational studies of drugs developed for treatment of cardiometabolic disease as novel therapeutic interventions to mitigate inflammation and improve outcomes in patients with COVID-19.

Source: Arteriosclerosis Thrombosis and Vascular Biology

DOI: 10.1161/atvbaha.120.314513

Authors: Bernard S. Kadosh, Michael S. Garshick, Juan Gaztanaga, Kathryn J. Moore, Jonathan D. Newman, Michael Pillinger, Ravichandran Ramasamy, Harmony R. Reynolds, Binita Shah, Judith Hochman, Glenn I. Fishman, Stuart D. Katz

Institutions: New York University, Winthrop-University Hospital, VA NY Harbor Healthcare System

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: American Heart Association, Office of Research and Development, Biomedical Laboratory Research and Development, VA Office of Research and Development, National Institutes of Health, National Heart, Lung, and Blood Institute, National Center for Research Resources, National Center for Advancing Translational Sciences

OpenAlex ID: W3044724589